New Genomic Technologies Conference & Exposition To Feature Latest Industry Advances in Princeton, NJ, July 16-18, 2001

Apr 02, 2001, 01:00 ET from Strategic Research Institute

    PRINCETON, N.J., April 2 /PRNewswire/ -- Late-breaking advances in genomic
 research in the related fields of target identification & validation,
 pharmacogenomics, SNP's, microarrays, and bioinformatics will be the focus of
 a comprehensive new meeting entitled "New Genomic Technologies Accelerating
 Drug Discovery," to take place in Princeton, NJ on July 16-18, 2001, announces
 Strategic Research Institute.
     The meeting, divided into five discrete sections are as follow: 1) target
 identification & validation, 2) pharmacogenomics & SNP's, 3) expression
 profiling & microarrays, 4) bioinformatics, and 5) proteomics, will feature
 prominent pharmaceutical and biotech scientists revealing their newest
 findings.
     Presenting papers on behalf of the industry will be Celera Genomics,
 Millennium Pharmaceuticals, Human Genome Sciences, Hoffmann-La Roche, Merck,
 GlaxoSmithKline, Schering-Plough, Bristol-Myers Squibb, DuPont
 Pharmaceuticals, Affymetrix, Wyeth-Ayerst, CuraGen, Incyte Genomics, Myriad
 Genetics, Ciphergen Biosystems, Orchid Biosciences, Nanogen, Rosetta
 Inpharmatics, Genomics Research Institute of the Novartis Foundation,
 Genaissance Pharmaceuticals, Genometrix, Proteome Inc., AxCell Biosciences,
 Neogenesis, Exelixis, and Galapagos Genomics.
 
     To receive the full agenda and/or register for the conference, please
 contact Jon E. Liong of Strategic Research Institute at
 jliong@srinstitute.com or 212-967-0095, x243 (please include name, corporate
 affiliation, mailing address, and fax number).
     To register as an exhibitor or to sponsor a function, please contact Mark
 Alexay at malexay@srinstitute.com.
 
 

SOURCE Strategic Research Institute
    PRINCETON, N.J., April 2 /PRNewswire/ -- Late-breaking advances in genomic
 research in the related fields of target identification & validation,
 pharmacogenomics, SNP's, microarrays, and bioinformatics will be the focus of
 a comprehensive new meeting entitled "New Genomic Technologies Accelerating
 Drug Discovery," to take place in Princeton, NJ on July 16-18, 2001, announces
 Strategic Research Institute.
     The meeting, divided into five discrete sections are as follow: 1) target
 identification & validation, 2) pharmacogenomics & SNP's, 3) expression
 profiling & microarrays, 4) bioinformatics, and 5) proteomics, will feature
 prominent pharmaceutical and biotech scientists revealing their newest
 findings.
     Presenting papers on behalf of the industry will be Celera Genomics,
 Millennium Pharmaceuticals, Human Genome Sciences, Hoffmann-La Roche, Merck,
 GlaxoSmithKline, Schering-Plough, Bristol-Myers Squibb, DuPont
 Pharmaceuticals, Affymetrix, Wyeth-Ayerst, CuraGen, Incyte Genomics, Myriad
 Genetics, Ciphergen Biosystems, Orchid Biosciences, Nanogen, Rosetta
 Inpharmatics, Genomics Research Institute of the Novartis Foundation,
 Genaissance Pharmaceuticals, Genometrix, Proteome Inc., AxCell Biosciences,
 Neogenesis, Exelixis, and Galapagos Genomics.
 
     To receive the full agenda and/or register for the conference, please
 contact Jon E. Liong of Strategic Research Institute at
 jliong@srinstitute.com or 212-967-0095, x243 (please include name, corporate
 affiliation, mailing address, and fax number).
     To register as an exhibitor or to sponsor a function, please contact Mark
 Alexay at malexay@srinstitute.com.
 
 SOURCE  Strategic Research Institute